CD19 and sarcopenia: In the case of OS, multivariate analysis identified pTNM stage (HR = 4.830, 95% CI: 2.741–8.511, P < 0.001), CD19+ cells (HR = 0.210, 95% CI: 0.051–0.876, P = 0.032), sarcopenia (HR = 4.089, 95% CI: 1.214–13.832, P = 0.023) and CD3+/CD4+ cell–myosteatosis (P < 0.001) as independent prognostic factors (Table 3).